Inhibikase Therapeutics Announces Enrollment of First Patient in Phase 3 Study of IKT-001 for Pulmonary Arterial Hypertension

Inhibikase Therapeutics has announced the enrollment of the first patient in its global Phase 3 clinical trial, IMPROVE-PAH, evaluating IKT-001 for the treatment of pulmonary arterial hypertension (PAH). This marks a significant milestone in the development of IKT-001 and could be a positive catalyst for the company's stock as it progresses towards potential regulatory approval and commercialization.